Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.2983
-0.00970-3.15%
At close: -
$0.3200
0.027.27%
After Hours: 6:36 PM EDT
Comments
Loading...
Cognition Therapeutics Analyst Ratings and Price Targets | NASDAQ:CGTX | Benzinga
Cognition Therapeutics Inc has a consensus price target of $6.25 based on the ratings of 7 analysts. The high is $14 issued by Rodman & Renshaw on July 2, 2024. The low is $1.5 issued by B. Riley Securities on December 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on May 27, 2025, May 8, 2025, and March 24, 2025, respectively. With an average price target of $4 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 1150.00% upside for Cognition Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
B. Riley Securities
Rodman & Renshaw
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Cognition Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/27/2025 | Buy Now | 837.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $3 | Maintains | Buy | Get Alert |
| 05/08/2025 | Buy Now | 1150% | Chardan Capital | Daniil Gataulin59% | $8 → $4 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 1462.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $6 → $5 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 2400% | Chardan Capital | Daniil Gataulin59% | $11 → $8 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 3337.5% | Chardan Capital | Daniil Gataulin59% | $11 → $11 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | 368.75% | B. Riley Securities | Mayank Mamtani72% | $1 → $1.5 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2024 | Buy Now | 3337.5% | Chardan Capital | Daniil Gataulin59% | $11 → $11 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | 1775% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $6 | Maintains | Buy | Get Alert |
| 11/27/2024 | Buy Now | 1462.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 3337.5% | Chardan Capital | Daniil Gataulin59% | $11 → $11 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 1462.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 3337.5% | Chardan Capital | Daniil Gataulin59% | $11 → $11 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 1462.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $7 → $5 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 212.5% | B. Riley Securities | Mayank Mamtani72% | $5 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 08/01/2024 | Buy Now | 2087.5% | HC Wainwright & Co. | Raghuram Selvaraju44% | $10 → $7 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan72% | — | Downgrade | Overweight → Neutral | Get Alert |
| 07/02/2024 | Buy Now | 4275% | Rodman & Renshaw | Elemer Piros54% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | 3337.5% | Chardan Capital | Daniil Gataulin59% | → $11 | Initiates | → Buy | Get Alert |
| 05/29/2024 | Buy Now | 3025% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $10 | Initiates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 1462.5% | B. Riley Securities | Mayank Mamtani72% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 2712.5% | Oppenheimer | Jay Olson60% | $9 → $9 | Maintains | Outperform | Get Alert |
| 08/14/2023 | Buy Now | 1775% | Ladenburg Thalmann | Aydin Huseynov34% | $10 → $6 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 2712.5% | Oppenheimer | Jay Olson60% | → $9 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 2712.5% | Oppenheimer | Jay Olson60% | → $9 | Reiterates | → Outperform | Get Alert |
| 09/29/2022 | Buy Now | 3650% | Cantor Fitzgerald | Charles Duncan72% | → $12 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Cognition Therapeutics (CGTX) stock?
The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $3.00 expecting CGTX to rise to within 12 months (a possible 837.50% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cognition Therapeutics (CGTX)?
The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by HC Wainwright & Co., and Cognition Therapeutics maintained their buy rating.
When was the last upgrade for Cognition Therapeutics (CGTX)?
The last upgrade for Cognition Therapeutics Inc happened on December 19, 2024 when B. Riley Securities raised their price target to $1.5. B. Riley Securities previously had a neutral for Cognition Therapeutics Inc.
When was the last downgrade for Cognition Therapeutics (CGTX)?
The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Cognition Therapeutics (CGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
Is the Analyst Rating Cognition Therapeutics (CGTX) correct?
While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a maintained with a price target of $5.00 to $3.00. The current price Cognition Therapeutics (CGTX) is trading at is $0.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
